Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of kirenol in preparation of drug for treating multiple sclerosis

A technique for multiple sclerosis and chinonyl alcohol, applied in the field of medicine, can solve the problems of limited effect, high price, limited medicine and the like, and achieves the effects of low cost, delayed onset time, and alleviation of clinical symptoms

Inactive Publication Date: 2015-12-16
HUBEI UNIV OF ARTS & SCI
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But current evidence-based medical evidence-backed drugs are quite limited and expensive
At present, the domestic treatment of MS is limited by factors such as economic conditions and medical insurance reimbursement. Only a very small number of patients can be treated with interferon β, and most of them still use adrenal corticosteroids, immunosuppressants and other treatments, which have limited effects and severe side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of kirenol in preparation of drug for treating multiple sclerosis
  • Use of kirenol in preparation of drug for treating multiple sclerosis
  • Use of kirenol in preparation of drug for treating multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Chinonol as an Oral Drug in the Treatment of Multiple Sclerosis

[0020] Step 1: Experimental animals are divided into groups, disease models are established and treated, (the first group, Control group: normal mice; the second group, Control+Kirenol group: normal mice administered with Kirenol; the third group, EAE group, mice The EAE disease model was established; the fourth group, EAE+Kirenol group, the mice established the EAE disease model and gavaged Kirneol at the same time). Observe the clinical manifestations of the animals, record the onset time and disease score, take the lumbar cord for H&E pathological staining, and find that kinonol can significantly inhibit the lymphocyte infiltration of the central nervous system, and the control group found that kinonol does not affect the central nervous system of normal mice . The result is as Figure 2-3 shown. from Figure 2-3 It can be seen that kirenol significantly delayed the onset time of EAE and alleviated...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a use of kirenol in preparation of a drug for treating multiple sclerosis and belongs to the technical field of medicines. The invention discloses a use of kirenol in preparation of an oral drug for treating multiple sclerosis. Kirenol oral administration can induce sensitized CD4+T cell apoptosis caused by a mitochondrial pathway, substantially delays multiple sclerosis animal model-EAE disease time and substantially mitigates EAE clinical symptoms. Kirenol as an oral drug for treating multiple sclerosis has a low cost and a clear molecule mechanism and provides a novel drug for treating multiple sclerosis.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to the application of chinonol in the preparation of drugs for treating multiple sclerosis. Background technique [0002] Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. EAE Experimental allergic encephalomyelitis (EAE) is mainly mediated by specifically sensitized CD4+ T cells, characterized by mononuclear cell infiltration and demyelination around small blood vessels in the central nervous system. A characteristic autoimmune disease, it is an ideal animal model for human multiple sclerosis (MS). Multiple sclerosis should be diagnosed and treated early, follow the evidence of evidence-based medicine, and combine the economic conditions and wishes of patients, and carry out reasonable treatment. But currently, the drugs supported by evidence-based medical arguments are quite limited and expensive. At present, domestic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/047A61P25/00
Inventor 肖娟刘文卫杨海波杨林秦鑫范晓航龚文容肖鹏
Owner HUBEI UNIV OF ARTS & SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com